A maker of cardiac and vascular medical devices and preserved human tissues, Artivion helps surgeons treat aortic disease with products like the On-X mechanical heart valve, BioGlue surgical sealant, and aortic stent grafts, while its cryopreservation service banks donated heart valves and blood vessels. It began in 1984 as CryoLife, founded by Steven Anderson and Robert McNally as the first company to specialize in freezing human heart valves. In 2022 it renamed itself Artivion, a blend of "aorta," "innovation," and "vision."
Artivion completes acquisition of Endospan for $135 million upfront cash
Artivion, Inc. completed its acquisition of Endospan Ltd., an Israeli developer of the NEXUS Aortic Arch System, on May 18, 2026.
Show detailsHide details
The net purchase price was approximately $131.3 million, paid in cash by CryoLife Asia Pacific Pte. Ltd., a wholly owned subsidiary of Artivion, after offsetting loans under the Amended and Restated Loan Agreement.
The base purchase price was $175.0 million, subject to adjustments, with $16.5 million placed in an indemnity escrow and $1.0 million in an adjustment escrow.
Securityholders may receive up to $200.0 million in contingent consideration based on future performance of the NEXUS product, payable approximately two years after closing.
The acquisition was funded using Artivion's previously drawn $150 million delayed draw term loan, and the FDA approved the NEXUS PMA in April 2026.
The transaction was reported under Items 7.01 and 8.01 as a Regulation FD disclosure and other events, with the press release furnished as Exhibit 99.1.
7.01 Regulation FD Disclosure · 8.01 Other Events · 9.01 Financial Statements and Exhibits
Artivion stockholders elect all nine director nominees and approve executive compensation and EY ratification at 2026 annual meeting.
Stockholders approved, on a non-binding basis, the compensation of named executive officers, with 36,876,134 votes for, 2,291,059 against, and 151,868 abstaining.
Show detailsHide details
At the May 12, 2026 Annual Meeting, Artivion stockholders elected all nine nominated directors to serve until the next annual meeting.
Stockholders ratified the selection of Ernst & Young LLP as independent auditor for fiscal year ending December 31, 2026, with 44,294,062 votes for, 625,438 against, and 7,308 abstaining.
Director vote results ranged from 34,250,202 to 39,241,704 votes for each nominee, with broker non-votes of 5,607,747 on each director election.
The report was filed under Item 5.07 to disclose the final voting results of matters submitted to a vote of security holders.
5.07 Submission of Matters to a Vote of Security Holders
Artivion exercises option to acquire Endospan for $175M base price, net ~$135M
Artivion's subsidiary CryoLife Asia Pacific exercised its option to acquire Endospan on May 7, 2026, following FDA approval of Endospan's Nexus product on April 2, 2026.
Show detailsHide details
The base purchase price is $175.0 million, payable entirely in cash (Artivion's election), with an expected net purchase price of approximately $135.0 million after offsetting loans.
The agreement includes contingent consideration of up to $200.0 million based on future Nexus product performance, payable about two years after closing.
Closing is subject to customary conditions, including due diligence, regulatory approvals, and absence of legal restraints; expected to close in Q2 2026.
Artivion also reported Q1 2026 revenue of $116.3 million, up 18% GAAP and 12% constant currency year-over-year, with net income of $1.4 million.
1.01 Entry into a Material Definitive Agreement · 2.02 Results of Operations and Financial Condition · 9.01 Financial Statements and Exhibits
Artivion reports Q4 and full-year 2025 results with revenue growth and net income improvement.
Q4 2025 GAAP revenue was $116.0 million, up from $97.3 million in Q4 2024; full-year revenue was $441.3 million versus $388.5 million.
Show detailsHide details
Q4 2025 GAAP net income was $2.4 million ($0.05 per diluted share) versus a net loss of $(16.5) million in Q4 2024; full-year net income was $9.8 million versus a net loss of $(13.4) million.
Adjusted revenue for Q4 2025 was $118.3 million, up 18% on an adjusted constant currency basis; full-year adjusted revenue was $443.6 million, up 13%.
Adjusted EBITDA increased 29% to $22.7 million in Q4 2025 and 26% to $89.6 million for the full year.
For 2026, Artivion expects revenue of $486–$504 million (10%–14% adjusted constant currency growth) and adjusted EBITDA of $105–$110 million (18%–22% growth).
2.02 Results of Operations and Financial Condition · 9.01 Financial Statements and Exhibits
Artivion reports Q3 2025 revenue of $113.4M, up 18% GAAP, and raises full-year guidance.
Third quarter 2025 revenue was $113.4 million, up 18% on a GAAP basis and 16% on a non-GAAP constant currency basis versus $95.8 million in Q3 2024.
Show detailsHide details
Net income for Q3 2025 was $6.5 million, or $0.13 per diluted share, compared to a net loss of $(2.3) million, or $(0.05) per diluted share in Q3 2024.
Adjusted EBITDA increased 39% to $24.6 million in Q3 2025 from $17.7 million in Q3 2024.
The company raised its full-year 2025 constant currency revenue growth guidance to 13%-14% and adjusted EBITDA growth guidance to 24%-28%.
Artivion enrolled the first patient in the ARTIZEN U.S. Investigational Device Exemption trial for Arcevo.
2.02 Results of Operations and Financial Condition · 9.01 Financial Statements and Exhibits
Artivion amends credit agreement, extends maturity to 2031 and adds $150M facility
On September 12, 2025, Artivion entered into a Second Amendment to its Credit and Guaranty Agreement with Ares Capital Corporation as administrative agent.
Show detailsHide details
The amendment extends the maturity of existing term loans and revolving credit facility by one year to January 18, 2031.
Interest rate margins were reduced: term loans now bear SOFR plus 4.75% or base rate plus 3.75%; revolving loans bear SOFR plus 3.50% or base rate plus 2.50%.
A new $150.0 million secured delayed draw term loan facility was added, available until September 12, 2027, subject to leverage ratio and other conditions.
Proceeds from the new facility may be used for permitted acquisitions, investments, and capital expenditures; prepayments before July 18, 2027 may incur a 1.00% premium.
1.01 Entry into a Material Definitive Agreement · 2.03 Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement · 9.01 Financial Statements and Exhibits